ID 109939
Title Transcription
クリゾチニブ ガ ソウコウ シタ Performance Status フリョウ anaplastic lymphoma kinase イデンシ テンザ ヨウセイ ハイセンガン ノ 1レイ
Title Alternative
A case of anaplastic lymphoma kinase-positive non-small cell lung cancer with a poor performance status successfully treated with crizotinib
Author
Kajita, Keisuke The Post-graduate Education Center, Tokushima University Hospital
Sato, Seidai Department of Respiratory Medicine and Rheumatology, Tokushima University Hospital Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Toyoda, Yuko Department of Respiratory Medicine and Rheumatology, Tokushima University Hospital Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Sakaguchi, Satoshi Department of Respiratory Medicine and Rheumatology, Tokushima University Hospital
Tezuka, Toshifumi Department of Respiratory Medicine and Rheumatology, Tokushima University Hospital KAKEN Search Researchers
Goto, Hisatsugu Department of Respiratory Medicine and Rheumatology, Tokushima University Hospital Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Hanibuchi, Masaki Department of Respiratory Medicine and Rheumatology, Tokushima University Hospital KAKEN Search Researchers
Nishioka, Yasuhiko Department of Respiratory Medicine and Rheumatology, Tokushima University Hospital Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Keywords
crizotinib
anaplastic lymphoma kinase
non-small cell lung cancer
performance status
Content Type
Journal Article
Description
A 27-year-old female was referred to our hospital for further examination of hoarseness, cough, and hemoptysis. Positron emission tomography-computed tomography revealed FDG accumulation in a huge mass in the left lower lobe, lymph nodes in the hilum, mediastinum and right cervical lesion left scapula and vertebral body. Further examination yielded the diagnosis of primary lung adenocarcinoma (cT2aN3M1b : Stage IV) harboring the anaplastic lymphoma kinase (ALK) fusion oncogene. Although her general condition was getting worse due to rapid increase of the pleural effusion, crizotinib promptly diminish the pleural effusion and ameliorated the patient’s condition. The adverse events of crizotinib, such as nausea, vomiting and visual disturbance, were generally mild and well tolerable during treatment. These findings suggest that crizotinib is a promising candidate for ALK-positive non-small cell lung cancer patients even with poor performances.
Journal Title
四国医学雑誌
ISSN
00373699
NCID
AN00102041
Publisher
徳島医学会
Volume
71
Issue
5-6
Start Page
141
End Page
148
Sort Key
141
Published Date
2015-12-25
EDB ID
FullText File
language
jpn
TextVersion
Publisher
departments
University Hospital
Medical Sciences